Skip to main content
HUMA
NASDAQ Life Sciences

以色列卫生部接受Humacyte的Symvess MAA，启动180天审查

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
7
Price
$0.708
Mkt Cap
$152.638M
52W Low
$0.547
52W High
$2.93
Market data snapshot near publication time

summarizeSummary

Humacyte宣布，以色列卫生部已接受其对Symvess的上市授权申请（MAA），Symvess是其用于血管创伤修复的生物工程血管，启动180个工作日的审查期。这一发展是在公司之前披露提交以色列批准后发生的。对于Humacyte，一家面临持续经营警告，并依赖稀释性融资的生物技术小盘公司（如其最近的10-K和PRE 14A文件中强调的那样），这是一个积极的步骤，以扩大其FDA批准产品在国际市场的商业范围。成功的市场扩张对于公司产生收入和解决其财务挑战至关重要。投资者应监测180天审查期的结果，以获取Symvess国际商业化的进一步更新。

在该公告发布时，HUMA的交易价格为$0.71，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1.5亿。 52周交易区间为$0.55至$2.93。 这则新闻被评估为积极市场情绪，重要性评分为7/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed HUMA - Latest Insights

HUMA
Apr 28, 2026, 4:52 PM EDT
Filing Type: DEF 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Future Capital Raises
Sentiment: Neutral
View Wiseek Article
HUMA
Apr 24, 2026, 8:09 AM EDT
Filing Type: 8-K
Importance Score:
7
Humacyte Reclaims Global Commercial Rights for Symvess from Fresenius
Sentiment: Positive
View Wiseek Article
HUMA
Apr 21, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Israeli Ministry of Health Accepts Humacyte's Symvess MAA, Initiating 180-Day Review
Sentiment: Positive
View Wiseek Article
HUMA
Apr 17, 2026, 4:30 PM EDT
Filing Type: PRE 14A
Importance Score:
8
Humacyte Seeks Shareholder Approval to Increase Authorized Shares by 200 Million, Paving Way for Significant Future Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 4:45 PM EDT
Filing Type: 10-K
Importance Score:
9
Humacyte Issues Going Concern Warning Amidst Low Revenue and Dilutive Financing
Sentiment: Negative
View Wiseek Article
HUMA
Mar 27, 2026, 7:00 AM EDT
Source: Reuters
Importance Score:
8
Humacyte Reports Wider-Than-Expected Q4 Losses, Missing Operating and Net Income Estimates
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:33 PM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Prices $20M Registered Direct Offering at Discount, Securing Capital for Operations
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 4:26 PM EDT
Filing Type: 424B3
Importance Score:
9
Humacyte Finalizes $20M Offering at Deep Discount, Discloses Substantial Doubt About Going Concern
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:30 AM EDT
Source: GlobeNewswire
Importance Score:
8
$20M Registered Direct Offering Priced by Humacyte, Signaling Share Dilution
Sentiment: Negative
View Wiseek Article
HUMA
Mar 19, 2026, 8:25 AM EDT
Filing Type: 8-K
Importance Score:
8
Humacyte Halts $60M ATM Offering, Secures Saudi Arabia Deal, and Files for Israeli Approval
Sentiment: Positive
View Wiseek Article